Replies to post #1615 on Sorrento Therapeutics Inc (SRNE)

[stock1ace1]

This is why co. Rejected 2 buyout offers ~> (Read close)

The Company is in active late-stage licensing and collaboration discussions with leading biopharmaceutical companies for the Company’s immuno-oncology products, including multiple targets to be deployed within the KOKI DAR-T platform. The Company believes that these pending transactions alone represent potential short- and long-term value creation significantly exceeding the current all cash proposal.

Dr. Henry Ji, Chairman and Chief Executive Officer, said, "the Sorrento Board of Directors and management team are committed to serving the best interests of the Company and Sorrento stockholders, and are confident in the Company's strategic direction and our ability to implement it.”

[stock1ace1]

“The Company believes that these pending transactions alone represent potential short- and long-term value creation significantly exceeding the current all cash proposal. “